Novo Nordisk

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. 

CEO
Maziar Mike Doustdar
CEOMaziar Mike Doustdar
Employees
68,794
Employees68,794
Headquarters
Bagsværd, Capital Region
HeadquartersBagsværd, Capital Region
Founded
1923
Founded1923
Employees
68,794
Employees68,794

NVO Key Statistics

Market cap
189.60B
Market cap189.60B
Price-Earnings ratio
9.81
Price-Earnings ratio9.81
Dividend yield
3.06%
Dividend yield3.06%
Average volume
11.91M
Average volume11.91M
High today
$43.24
High today$43.24
Low today
$41.50
Low today$41.50
Open price
$42.43
Open price$42.43
Volume
26.04M
Volume26.04M
52 Week high
$64.16
52 Week high$64.16
52 Week low
$35.12
52 Week low$35.12

NVO News

The Motley Fool 4h
Novo Nordisk: 3 Key Takeaways for Long-Term Investors

On its third-quarter 2026 earnings call, held on Nov. 4, 2026, Novo Nordisk (NVO +4.95%) announced raised full-year financial guidance alongside a return to vol...

Novo Nordisk: 3 Key Takeaways for Long-Term Investors
The Wall Street Journal 8h
Novo Nordisk Stock Jumps After Outlook Improves

Novo Nordisk’s U.S.-traded shares were up nearly 5% Wednesday, their largest increase since June, after the Danish drugmaker improved its sales outlook. The co...

Novo Nordisk Stock Jumps After Outlook Improves
The Motley Fool 9h
Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know

Novo Nordisk (NVO +5.24%) gave investors a lot of what they wanted on Wednesday. Third-quarter sales rose 4% at constant exchange rates to about $11.9 billion,...

Novo Nordisk Stock Jumped After Earnings — But Its CEO Won't Give 2027 Guidance. Here's What Investors Should Know

Analyst ratings

50%

of 6 ratings
Buy
16.7%
Hold
50%
Sell
33.3%

More NVO News

Benzinga 17h
Novo Nordisk Raises 2026 Outlook As Wegovy Pill Shines

Novo Nordisk A/S (NYSE:NVO) stock rose Wednesday after the drugmaker reported better-than-expected third-quarter earnings and raised its full-year outlook. Nov...

Novo Nordisk Raises 2026 Outlook As Wegovy Pill Shines
Simply Wall St 17h
Is Novo Nordisk Reasonable After Its 58% Fall?

has seen its share price fall sharply in recent years, even as attention stays fixed on its diabetes and obesity franchise. With the stock down heavily over a 3...

Is Novo Nordisk Reasonable After Its 58% Fall?
The Motley Fool 18h
Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.

Viking Therapeutics (VKTX -2.76%) has been a company to watch over the past few years. That's because the biotech is involved in one of the healthcare market's...

Viking Therapeutics Trades 23% Below Its Own $35 Secondary Offering Price. Here's Why That Could Be a Gift for Patient Investors.
The Wall Street Journal 18h
Health Care Roundup: Market Talk

Yves Herman / Reuters The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET....

Health Care Roundup: Market Talk
The Motley Fool 4d
Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?

Shares of Novo Nordisk (NVO +2.20%) have declined roughly 70% from their 2024 high. The stock is now below its level in mid-2021, when it first introduced the W...

Novo Nordisk Trades at 10 Times Earnings While Buying Back Billions in Stock. Is This the Bottom?
Simply Wall St 6d
Novo Nordisk Could Be 62% Undervalued On GLP 1 Growth Expectations

Advertisement Recent Share Performance and Business Profile Novo Nordisk (NYSE:NVO) has been trading around US$39.14 per share, with the price moving higher o...

24/7 Wall St. 7d
Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases

Investing Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases Eli Lilly just posted a quarter that left...

Eli Lilly Jumps 8% as Strong Quarter Lifts Revenue Outlook; Novo Nordisk Ticks Up, Viking Therapeutics Eases

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.